Drugs / Bioengineered Internal Anal Sphincter
Bioengineered Internal Anal Sphincter
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05616208 | Nov 2022 → Jul 2027 expected | — | Cellf Bio LLC | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bioengineered Internal Anal Sphincter | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05616208 ↗ |
| Modality | Cell therapy | “implanted internal anal sphincter (IAS) bioengineered from autologous cells” NCT05616208 ↗ |
| Route | Other | “undergo an implantation surgery of the bioengineered BioSphincter(TM).” NCT05616208 ↗ |